Aligos Therapeutics (ALGS) Share-based Compensation (2019 - 2026)

Aligos Therapeutics has reported Share-based Compensation for 8 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 37.02% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.4 million (down 20.15% YoY), and the FY2025 full-year result was $5.0 million, down 40.32% from the prior year.
• Share-based Compensation for Q1 2026 stood at $1.3 million, down from $1.5 million in the prior quarter.
• The five-year high for Share-based Compensation was $4.0 million in Q2 2022, with the low at $959000.0 in Q1 2025.
• Historically, Share-based Compensation has averaged $2.5 million across 5 years, with a median of $2.6 million in 2023.
• Annual changes were most pronounced in 2025 — Share-based Compensation plunged 63.78% — and 2026, when it soared 37.02%.
• Aligos Therapeutics' Share-based Compensation stood at $3.4 million in 2022, then fell by 24.39% to $2.6 million in 2023, then sank by 33.99% to $1.7 million in 2024, then fell by 14.49% to $1.5 million in 2025, then fell by 9.88% to $1.3 million in 2026.
• The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $1.5 million (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.